nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—DPP4—embryo—testicular cancer	0.0233	0.113	CbGeAlD
Vidarabine—ADK—seminal vesicle—testicular cancer	0.0226	0.109	CbGeAlD
Vidarabine—DPP4—seminal vesicle—testicular cancer	0.0219	0.106	CbGeAlD
Vidarabine—ADORA2A—gonad—testicular cancer	0.0182	0.0881	CbGeAlD
Vidarabine—ADK—gonad—testicular cancer	0.0163	0.0791	CbGeAlD
Vidarabine—ADA—testis—testicular cancer	0.0144	0.0698	CbGeAlD
Vidarabine—ADK—female gonad—testicular cancer	0.0133	0.0643	CbGeAlD
Vidarabine—ADORA2A—testis—testicular cancer	0.0131	0.0635	CbGeAlD
Vidarabine—DPP4—female gonad—testicular cancer	0.0129	0.0623	CbGeAlD
Vidarabine—ADK—testis—testicular cancer	0.0118	0.057	CbGeAlD
Vidarabine—DPP4—testis—testicular cancer	0.0114	0.0553	CbGeAlD
Vidarabine—ADA—lymph node—testicular cancer	0.0105	0.0506	CbGeAlD
Vidarabine—ADK—lymph node—testicular cancer	0.00854	0.0413	CbGeAlD
Vidarabine—DPP4—lymph node—testicular cancer	0.00828	0.0401	CbGeAlD
Vidarabine—Acute coronary syndrome—Etoposide—testicular cancer	0.00268	0.00338	CcSEcCtD
Vidarabine—Chest pain—Bleomycin—testicular cancer	0.00268	0.00337	CcSEcCtD
Vidarabine—Myocardial infarction—Etoposide—testicular cancer	0.00266	0.00336	CcSEcCtD
Vidarabine—Discomfort—Bleomycin—testicular cancer	0.00265	0.00333	CcSEcCtD
Vidarabine—Urticaria—Chlorambucil—testicular cancer	0.00263	0.00332	CcSEcCtD
Vidarabine—Pain—Vinblastine—testicular cancer	0.0026	0.00328	CcSEcCtD
Vidarabine—Atrioventricular block—Doxorubicin—testicular cancer	0.0026	0.00327	CcSEcCtD
Vidarabine—Anaphylactic shock—Bleomycin—testicular cancer	0.00257	0.00324	CcSEcCtD
Vidarabine—Vision blurred—Ifosfamide—testicular cancer	0.00253	0.00319	CcSEcCtD
Vidarabine—Ventricular tachycardia—Doxorubicin—testicular cancer	0.00252	0.00317	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—testicular cancer	0.0025	0.00316	CcSEcCtD
Vidarabine—Tinnitus—Cisplatin—testicular cancer	0.00248	0.00313	CcSEcCtD
Vidarabine—Flushing—Cisplatin—testicular cancer	0.00247	0.00311	CcSEcCtD
Vidarabine—Cardiac disorder—Cisplatin—testicular cancer	0.00247	0.00311	CcSEcCtD
Vidarabine—Agitation—Ifosfamide—testicular cancer	0.00247	0.00311	CcSEcCtD
Vidarabine—Discomfort—Dactinomycin—testicular cancer	0.00247	0.00311	CcSEcCtD
Vidarabine—Angioedema—Ifosfamide—testicular cancer	0.00246	0.0031	CcSEcCtD
Vidarabine—Hypersensitivity—Chlorambucil—testicular cancer	0.00244	0.00308	CcSEcCtD
Vidarabine—Hypoaesthesia—Etoposide—testicular cancer	0.00243	0.00306	CcSEcCtD
Vidarabine—Mediastinal disorder—Cisplatin—testicular cancer	0.0024	0.00302	CcSEcCtD
Vidarabine—Hypotension—Bleomycin—testicular cancer	0.0024	0.00302	CcSEcCtD
Vidarabine—Asthenia—Chlorambucil—testicular cancer	0.00238	0.003	CcSEcCtD
Vidarabine—Arrhythmia—Cisplatin—testicular cancer	0.00238	0.003	CcSEcCtD
Vidarabine—Palpitations—Ifosfamide—testicular cancer	0.00238	0.00299	CcSEcCtD
Vidarabine—Cough—Ifosfamide—testicular cancer	0.00235	0.00296	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.00234	0.00295	CcSEcCtD
Vidarabine—Convulsion—Ifosfamide—testicular cancer	0.00233	0.00294	CcSEcCtD
Vidarabine—Hypertension—Ifosfamide—testicular cancer	0.00232	0.00292	CcSEcCtD
Vidarabine—Paraesthesia—Bleomycin—testicular cancer	0.0023	0.00291	CcSEcCtD
Vidarabine—Dyspnoea—Bleomycin—testicular cancer	0.00229	0.00288	CcSEcCtD
Vidarabine—Chest pain—Ifosfamide—testicular cancer	0.00229	0.00288	CcSEcCtD
Vidarabine—Flushing—Etoposide—testicular cancer	0.00226	0.00285	CcSEcCtD
Vidarabine—Cardiac disorder—Etoposide—testicular cancer	0.00226	0.00285	CcSEcCtD
Vidarabine—Discomfort—Ifosfamide—testicular cancer	0.00226	0.00285	CcSEcCtD
Vidarabine—Hypersensitivity—Vinblastine—testicular cancer	0.00224	0.00282	CcSEcCtD
Vidarabine—Mediastinal disorder—Etoposide—testicular cancer	0.0022	0.00277	CcSEcCtD
Vidarabine—Pain—Bleomycin—testicular cancer	0.00219	0.00277	CcSEcCtD
Vidarabine—Anaphylactic shock—Ifosfamide—testicular cancer	0.00219	0.00276	CcSEcCtD
Vidarabine—Vision blurred—Cisplatin—testicular cancer	0.00218	0.00275	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00218	0.00275	CcSEcCtD
Vidarabine—Asthenia—Vinblastine—testicular cancer	0.00218	0.00275	CcSEcCtD
Vidarabine—Tremor—Cisplatin—testicular cancer	0.00217	0.00274	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—testicular cancer	0.00215	0.00272	CcSEcCtD
Vidarabine—Hyperhidrosis—Ifosfamide—testicular cancer	0.00212	0.00267	CcSEcCtD
Vidarabine—Vomiting—Chlorambucil—testicular cancer	0.00211	0.00266	CcSEcCtD
Vidarabine—Dysgeusia—Etoposide—testicular cancer	0.00208	0.00262	CcSEcCtD
Vidarabine—Back pain—Etoposide—testicular cancer	0.00205	0.00259	CcSEcCtD
Vidarabine—Hypotension—Ifosfamide—testicular cancer	0.00205	0.00258	CcSEcCtD
Vidarabine—Pain—Dactinomycin—testicular cancer	0.00205	0.00258	CcSEcCtD
Vidarabine—Urticaria—Bleomycin—testicular cancer	0.00204	0.00257	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—testicular cancer	0.00202	0.00255	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—testicular cancer	0.00202	0.00254	CcSEcCtD
Vidarabine—Dizziness—Vinblastine—testicular cancer	0.00201	0.00253	CcSEcCtD
Vidarabine—Convulsion—Cisplatin—testicular cancer	0.00201	0.00253	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—testicular cancer	0.002	0.00252	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.002	0.00252	CcSEcCtD
Vidarabine—Nausea—Chlorambucil—testicular cancer	0.00197	0.00248	CcSEcCtD
Vidarabine—Paraesthesia—Ifosfamide—testicular cancer	0.00197	0.00248	CcSEcCtD
Vidarabine—Anxiety—Cisplatin—testicular cancer	0.00197	0.00248	CcSEcCtD
Vidarabine—Dyspnoea—Ifosfamide—testicular cancer	0.00196	0.00247	CcSEcCtD
Vidarabine—Somnolence—Ifosfamide—testicular cancer	0.00195	0.00246	CcSEcCtD
Vidarabine—Discomfort—Cisplatin—testicular cancer	0.00195	0.00246	CcSEcCtD
Vidarabine—Affect lability—Epirubicin—testicular cancer	0.00194	0.00245	CcSEcCtD
Vidarabine—Vomiting—Vinblastine—testicular cancer	0.00193	0.00244	CcSEcCtD
Vidarabine—Headache—Vinblastine—testicular cancer	0.0019	0.0024	CcSEcCtD
Vidarabine—Anaphylactic shock—Cisplatin—testicular cancer	0.00189	0.00238	CcSEcCtD
Vidarabine—Hypersensitivity—Bleomycin—testicular cancer	0.00189	0.00238	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—testicular cancer	0.00188	0.00237	CcSEcCtD
Vidarabine—Pain—Ifosfamide—testicular cancer	0.00188	0.00236	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—testicular cancer	0.00187	0.00236	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—testicular cancer	0.00187	0.00236	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—testicular cancer	0.00187	0.00235	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—testicular cancer	0.00187	0.00235	CcSEcCtD
Vidarabine—Cough—Etoposide—testicular cancer	0.00185	0.00233	CcSEcCtD
Vidarabine—Tachycardia—Cisplatin—testicular cancer	0.00185	0.00233	CcSEcCtD
Vidarabine—Asthenia—Bleomycin—testicular cancer	0.00184	0.00232	CcSEcCtD
Vidarabine—Convulsion—Etoposide—testicular cancer	0.00184	0.00232	CcSEcCtD
Vidarabine—Hypertension—Etoposide—testicular cancer	0.00183	0.00231	CcSEcCtD
Vidarabine—Hyperhidrosis—Cisplatin—testicular cancer	0.00183	0.0023	CcSEcCtD
Vidarabine—Chest pain—Etoposide—testicular cancer	0.00181	0.00228	CcSEcCtD
Vidarabine—Nausea—Vinblastine—testicular cancer	0.00181	0.00228	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—testicular cancer	0.0018	0.00227	CcSEcCtD
Vidarabine—Discomfort—Etoposide—testicular cancer	0.00179	0.00225	CcSEcCtD
Vidarabine—Hypotension—Cisplatin—testicular cancer	0.00177	0.00223	CcSEcCtD
Vidarabine—Hypersensitivity—Dactinomycin—testicular cancer	0.00176	0.00222	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—testicular cancer	0.00175	0.00221	CcSEcCtD
Vidarabine—Urticaria—Ifosfamide—testicular cancer	0.00174	0.0022	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—testicular cancer	0.00174	0.00219	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—testicular cancer	0.00173	0.00218	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—testicular cancer	0.00173	0.00218	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00172	0.00217	CcSEcCtD
Vidarabine—Asthenia—Dactinomycin—testicular cancer	0.00172	0.00216	CcSEcCtD
Vidarabine—Paraesthesia—Cisplatin—testicular cancer	0.0017	0.00214	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—testicular cancer	0.00169	0.00213	CcSEcCtD
Vidarabine—Dyspnoea—Cisplatin—testicular cancer	0.00169	0.00213	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—testicular cancer	0.00167	0.00211	CcSEcCtD
Vidarabine—Vomiting—Bleomycin—testicular cancer	0.00163	0.00206	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—testicular cancer	0.00163	0.00205	CcSEcCtD
Vidarabine—Hypotension—Etoposide—testicular cancer	0.00162	0.00204	CcSEcCtD
Vidarabine—Rash—Bleomycin—testicular cancer	0.00162	0.00204	CcSEcCtD
Vidarabine—Pain—Cisplatin—testicular cancer	0.00162	0.00204	CcSEcCtD
Vidarabine—Dermatitis—Bleomycin—testicular cancer	0.00162	0.00204	CcSEcCtD
Vidarabine—Hypersensitivity—Ifosfamide—testicular cancer	0.00162	0.00204	CcSEcCtD
Vidarabine—Pollakiuria—Epirubicin—testicular cancer	0.00158	0.00199	CcSEcCtD
Vidarabine—Asthenia—Ifosfamide—testicular cancer	0.00157	0.00198	CcSEcCtD
Vidarabine—Sweating—Methotrexate—testicular cancer	0.00156	0.00197	CcSEcCtD
Vidarabine—Paraesthesia—Etoposide—testicular cancer	0.00156	0.00196	CcSEcCtD
Vidarabine—Dyspnoea—Etoposide—testicular cancer	0.00154	0.00195	CcSEcCtD
Vidarabine—Somnolence—Etoposide—testicular cancer	0.00154	0.00194	CcSEcCtD
Vidarabine—Nausea—Bleomycin—testicular cancer	0.00152	0.00192	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—testicular cancer	0.00152	0.00192	CcSEcCtD
Vidarabine—Vomiting—Dactinomycin—testicular cancer	0.00152	0.00192	CcSEcCtD
Vidarabine—Rash—Dactinomycin—testicular cancer	0.00151	0.0019	CcSEcCtD
Vidarabine—Pain—Etoposide—testicular cancer	0.00148	0.00187	CcSEcCtD
Vidarabine—Sweating—Epirubicin—testicular cancer	0.00146	0.00184	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—testicular cancer	0.00146	0.00184	CcSEcCtD
Vidarabine—Dizziness—Ifosfamide—testicular cancer	0.00145	0.00183	CcSEcCtD
Vidarabine—Nausea—Dactinomycin—testicular cancer	0.00142	0.00179	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—testicular cancer	0.00141	0.00178	CcSEcCtD
Vidarabine—Vomiting—Ifosfamide—testicular cancer	0.00139	0.00176	CcSEcCtD
Vidarabine—Hypersensitivity—Cisplatin—testicular cancer	0.00139	0.00176	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—testicular cancer	0.00139	0.00175	CcSEcCtD
Vidarabine—Rash—Ifosfamide—testicular cancer	0.00138	0.00174	CcSEcCtD
Vidarabine—Dermatitis—Ifosfamide—testicular cancer	0.00138	0.00174	CcSEcCtD
Vidarabine—Urticaria—Etoposide—testicular cancer	0.00138	0.00173	CcSEcCtD
Vidarabine—Tinnitus—Methotrexate—testicular cancer	0.00136	0.00172	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—testicular cancer	0.00136	0.00171	CcSEcCtD
Vidarabine—Asthenia—Cisplatin—testicular cancer	0.00136	0.00171	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—testicular cancer	0.00136	0.00171	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—testicular cancer	0.00135	0.0017	CcSEcCtD
Vidarabine—Mediastinal disorder—Methotrexate—testicular cancer	0.00132	0.00166	CcSEcCtD
Vidarabine—Nausea—Ifosfamide—testicular cancer	0.0013	0.00164	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—testicular cancer	0.00129	0.00162	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—testicular cancer	0.00128	0.00161	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—testicular cancer	0.00127	0.00161	CcSEcCtD
Vidarabine—Flushing—Epirubicin—testicular cancer	0.00127	0.0016	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—testicular cancer	0.00127	0.0016	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—testicular cancer	0.00126	0.00159	CcSEcCtD
Vidarabine—Dysgeusia—Methotrexate—testicular cancer	0.00125	0.00157	CcSEcCtD
Vidarabine—Asthenia—Etoposide—testicular cancer	0.00124	0.00157	CcSEcCtD
Vidarabine—Mediastinal disorder—Epirubicin—testicular cancer	0.00123	0.00155	CcSEcCtD
Vidarabine—Back pain—Methotrexate—testicular cancer	0.00123	0.00155	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—testicular cancer	0.00122	0.00154	CcSEcCtD
Vidarabine—Vomiting—Cisplatin—testicular cancer	0.0012	0.00152	CcSEcCtD
Vidarabine—Vision blurred—Methotrexate—testicular cancer	0.0012	0.00151	CcSEcCtD
Vidarabine—Rash—Cisplatin—testicular cancer	0.00119	0.0015	CcSEcCtD
Vidarabine—Dermatitis—Cisplatin—testicular cancer	0.00119	0.0015	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—testicular cancer	0.00118	0.00149	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—testicular cancer	0.00117	0.00148	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—testicular cancer	0.00117	0.00148	CcSEcCtD
Vidarabine—Tension—Epirubicin—testicular cancer	0.00117	0.00147	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—testicular cancer	0.00117	0.00147	CcSEcCtD
Vidarabine—Nervousness—Epirubicin—testicular cancer	0.00116	0.00146	CcSEcCtD
Vidarabine—Back pain—Epirubicin—testicular cancer	0.00115	0.00145	CcSEcCtD
Vidarabine—Dizziness—Etoposide—testicular cancer	0.00115	0.00144	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00114	0.00144	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—testicular cancer	0.00113	0.00142	CcSEcCtD
Vidarabine—Nausea—Cisplatin—testicular cancer	0.00112	0.00142	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—testicular cancer	0.00112	0.00141	CcSEcCtD
Vidarabine—Cough—Methotrexate—testicular cancer	0.00111	0.0014	CcSEcCtD
Vidarabine—Convulsion—Methotrexate—testicular cancer	0.0011	0.00139	CcSEcCtD
Vidarabine—Vomiting—Etoposide—testicular cancer	0.0011	0.00139	CcSEcCtD
Vidarabine—Agitation—Epirubicin—testicular cancer	0.00109	0.00138	CcSEcCtD
Vidarabine—Rash—Etoposide—testicular cancer	0.00109	0.00138	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—testicular cancer	0.00109	0.00138	CcSEcCtD
Vidarabine—Headache—Etoposide—testicular cancer	0.00109	0.00137	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—testicular cancer	0.00108	0.00136	CcSEcCtD
Vidarabine—Tension—Doxorubicin—testicular cancer	0.00108	0.00136	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—testicular cancer	0.00108	0.00136	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—testicular cancer	0.00107	0.00135	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—testicular cancer	0.00107	0.00135	CcSEcCtD
Vidarabine—Syncope—Epirubicin—testicular cancer	0.00107	0.00135	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—testicular cancer	0.00107	0.00134	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—testicular cancer	0.00105	0.00133	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—testicular cancer	0.00105	0.00132	CcSEcCtD
Vidarabine—Cough—Epirubicin—testicular cancer	0.00104	0.00131	CcSEcCtD
Vidarabine—Anaphylactic shock—Methotrexate—testicular cancer	0.00104	0.00131	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—testicular cancer	0.00104	0.00131	CcSEcCtD
Vidarabine—Convulsion—Epirubicin—testicular cancer	0.00103	0.0013	CcSEcCtD
Vidarabine—Nausea—Etoposide—testicular cancer	0.00103	0.0013	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—testicular cancer	0.00103	0.00129	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—testicular cancer	0.00101	0.00128	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—testicular cancer	0.00101	0.00128	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—testicular cancer	0.00101	0.00127	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—testicular cancer	0.001	0.00126	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—testicular cancer	0.001	0.00126	CcSEcCtD
Vidarabine—Dry mouth—Epirubicin—testicular cancer	0.000991	0.00125	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—testicular cancer	0.000987	0.00124	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—testicular cancer	0.000973	0.00123	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—testicular cancer	0.000971	0.00122	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—testicular cancer	0.00097	0.00122	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—testicular cancer	0.000968	0.00122	CcSEcCtD
Vidarabine—Cough—Doxorubicin—testicular cancer	0.000961	0.00121	CcSEcCtD
Vidarabine—Shock—Epirubicin—testicular cancer	0.000956	0.0012	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—testicular cancer	0.000954	0.0012	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—testicular cancer	0.000951	0.0012	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—testicular cancer	0.000948	0.00119	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000946	0.00119	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—testicular cancer	0.000939	0.00118	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—testicular cancer	0.000937	0.00118	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—testicular cancer	0.000934	0.00118	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—testicular cancer	0.000932	0.00117	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—testicular cancer	0.000926	0.00117	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—testicular cancer	0.000925	0.00117	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—testicular cancer	0.000923	0.00116	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—testicular cancer	0.000917	0.00116	CcSEcCtD
Vidarabine—Hypotension—Epirubicin—testicular cancer	0.000908	0.00114	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000899	0.00113	CcSEcCtD
Vidarabine—Pain—Methotrexate—testicular cancer	0.000887	0.00112	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000885	0.00112	CcSEcCtD
Vidarabine—Shock—Doxorubicin—testicular cancer	0.000884	0.00111	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—testicular cancer	0.000877	0.00111	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—testicular cancer	0.000872	0.0011	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000869	0.00109	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—testicular cancer	0.000866	0.00109	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—testicular cancer	0.000863	0.00109	CcSEcCtD
Vidarabine—Hypotension—Doxorubicin—testicular cancer	0.00084	0.00106	CcSEcCtD
Vidarabine—Pain—Epirubicin—testicular cancer	0.000831	0.00105	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—testicular cancer	0.000824	0.00104	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000819	0.00103	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—testicular cancer	0.000807	0.00102	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—testicular cancer	0.000801	0.00101	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—testicular cancer	0.000799	0.00101	CcSEcCtD
Vidarabine—Urticaria—Epirubicin—testicular cancer	0.000772	0.000972	CcSEcCtD
Vidarabine—Pain—Doxorubicin—testicular cancer	0.000768	0.000969	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—testicular cancer	0.000765	0.000964	CcSEcCtD
Vidarabine—Asthenia—Methotrexate—testicular cancer	0.000745	0.000938	CcSEcCtD
Vidarabine—Hypersensitivity—Epirubicin—testicular cancer	0.000716	0.000902	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—testicular cancer	0.000714	0.0009	CcSEcCtD
Vidarabine—Asthenia—Epirubicin—testicular cancer	0.000697	0.000878	CcSEcCtD
Vidarabine—Dizziness—Methotrexate—testicular cancer	0.000686	0.000865	CcSEcCtD
Vidarabine—Hypersensitivity—Doxorubicin—testicular cancer	0.000662	0.000834	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—testicular cancer	0.00066	0.000832	CcSEcCtD
Vidarabine—Rash—Methotrexate—testicular cancer	0.000654	0.000825	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—testicular cancer	0.000654	0.000824	CcSEcCtD
Vidarabine—Headache—Methotrexate—testicular cancer	0.00065	0.000819	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—testicular cancer	0.000645	0.000813	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—testicular cancer	0.000642	0.000809	CcSEcCtD
Vidarabine—Vomiting—Epirubicin—testicular cancer	0.000618	0.000778	CcSEcCtD
Vidarabine—Nausea—Methotrexate—testicular cancer	0.000616	0.000777	CcSEcCtD
Vidarabine—Rash—Epirubicin—testicular cancer	0.000612	0.000772	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—testicular cancer	0.000612	0.000771	CcSEcCtD
Vidarabine—Headache—Epirubicin—testicular cancer	0.000608	0.000767	CcSEcCtD
Vidarabine—Dizziness—Doxorubicin—testicular cancer	0.000594	0.000749	CcSEcCtD
Vidarabine—Nausea—Epirubicin—testicular cancer	0.000577	0.000727	CcSEcCtD
Vidarabine—Vomiting—Doxorubicin—testicular cancer	0.000571	0.00072	CcSEcCtD
Vidarabine—Rash—Doxorubicin—testicular cancer	0.000567	0.000714	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—testicular cancer	0.000566	0.000713	CcSEcCtD
Vidarabine—Headache—Doxorubicin—testicular cancer	0.000563	0.00071	CcSEcCtD
Vidarabine—Nausea—Doxorubicin—testicular cancer	0.000534	0.000673	CcSEcCtD
